Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia
NCT05828108Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bitopertin in Diamond-Blackfan anemia (DBA), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Number of Participants With Response at 32 weeks. Started Jul 2023; status: completed.
02
Drugs
bitopertin
03
Conditions
Diamond-Blackfan anemia (DBA)
Beyond the preview
Go deeper on NCT05828108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828108.